| Title： | Guidelines for clinical application of mifepristone |
| Edition： | Original |
| Classification： | Standard guideline |
| Field： | Others |
| Countries and regions： | China |
| Guidelines users： | Clinicians, pharmacists, nurses and other stakeholders. |
| Evidence classification method： | The guideline will use the Grades of Recommendations Assessment, Development and Evaluation (GRADE) to rate the quality of evidence and to grade the strength of recommendations. |
| Development unit： | China Medical Education Association, Beijing Association of Holistic Integrative Medicine. |
| Registration time: | 2023-11-17 |
| Registration number： | PREPARE-2023CN916 |
| Purpose of the guideline: | A lot of medication risks related to mifepristone therapy still remain to be identified and standardized. This project aims to establish an evidenced-based practice guidelines for clinical application of mifepristone. |
Latest registration
